BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9003473)

  • 1. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Baccini C; Zaccaria A; Visani G; Buzzi M; Morelli A; Molinari AL; Salvucci M; Bendandi M; Rubboli D; Gherlinzoni F; Zanchini R; Tura S
    Eur J Haematol; 1996 Nov; 57(5):335-40. PubMed ID: 9003473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.
    Schroeder JR; Saah AJ; Hoover DR; Margolick JB; Ambinder RF; Martinez-Maza O; Breen EC; Jacobson LP; Variakojis D; Rowe DT; Armenian HK
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):979-84. PubMed ID: 10566552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
    Li D; Li G; Wang B
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with absence of Epstein-Barr virus in tumor tissue.
    Schroeder JR; Saah AJ; Ambinder RF; Martinez-Maza O; Crabb Breen E; Variakojis D; Margolick JB; Jacobson LP; Rowe DT; Hoover DR
    Clin Immunol; 1999 Dec; 93(3):239-44. PubMed ID: 10600334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys.
    Hannig H; Buske C; Mätz-Rensing K; Hunsmann G; Hiddemann W; Bodemer W
    Int J Cancer; 1998 Aug; 77(5):734-40. PubMed ID: 9688307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin's lymphomas: evidence from a meta-analysis.
    Huang YS; Zhou X; Yang ZF; Lv ZT
    Ann Hematol; 2018 Aug; 97(8):1317-1325. PubMed ID: 29750316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas.
    Iaffaioli RV; Frasci G; Palmieri G; Tagliaferri P; Montesarchio V; Pagliarulo C; Tortoriello A; Facchini G; Matano E; Lauria R
    Leuk Lymphoma; 1995 Mar; 17(1-2):147-53. PubMed ID: 7773152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
    Warzocha K; Bienvenu J; Ribeiro P; Moullet I; Dumontet C; Neidhardt-Berard EM; Coiffier B; Salles G
    Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
    Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
    Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
    Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
    Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
    J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma.
    Yawetz S; Cumberland WG; van der Meyden M; Martínez-Maza O
    Blood; 1995 Apr; 85(7):1843-9. PubMed ID: 7703491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered release of tumor necrosis factor and its soluble receptor in non-Hodgkin's lymphoma patients.
    Rathore VB; Advani SH; Nadkarni JJ
    Cancer Detect Prev; 1999; 23(3):226-31. PubMed ID: 10337001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkins lymphoma.
    Macia J; Gomez X; Esquerda A; Perez B; Callao V; Marzo C
    Leuk Lymphoma; 1996 Feb; 20(5-6):481-6. PubMed ID: 8833407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgE low affinity receptor (CD23) expression, Plasmodium falciparum specific IgE and tumor necrosis factor-alpha production in Thai uncomplicated and severe falciparum malaria patients.
    Kumsiri R; Troye-Blomberg M; Pattanapanyasat K; Krudsood S; Maneerat Y
    Acta Trop; 2016 Feb; 154():25-33. PubMed ID: 26519199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.